Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC), a biotechnology company focused on developing iPSC-derived cell therapies, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Brent Pfeiffenberger will deliver a company presentation, which will be available via on-demand webcast starting September 5, 2025, at 7:00 a.m. ET.
The management team will also be available for investor meetings during the conference on September 9-10, 2025 in New York. Interested parties can access the presentation through Century's website, where it will remain available for at least 30 days.
Positive
- None.
Negative
- None.
PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. In addition, members of management will be available for meetings with investors at the conference from September 9-10, 2025, in New York, NY.
The on-demand webcast of the company presentation will be available beginning at 7:00 a.m. ET on Friday, September 5, 2025, on the Investors page of Century’s website at www.centurytx.com. The webcast will be archived on the company’s website for at least 30 days.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company leveraging its expertise in cellular reprogramming, genetic engineering, and manufacturing to develop cell therapies with the potential to provide meaningful advantages over existing cell therapies. Century’s genetically engineered, iPSC-derived cell therapy pipeline includes programs designed to address autoimmune diseases and cancers. Century believes its commitment to developing off-the-shelf cell therapies will expand patient access and provide an opportunity to advance the course of autoimmune disease and cancer care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.
For More Information:
Century Therapeutics
Douglas Carr
Senior Vice President, Finance
investor.relations@centurytx.com
JPA Health
Sarah McCabe
smccabe@jpa.com
FAQ
When is Century Therapeutics (IPSC) presenting at the H.C. Wainwright Conference?
How can investors access Century Therapeutics' (IPSC) H.C. Wainwright conference presentation?
Will Century Therapeutics (IPSC) management be available for meetings during the conference?
What type of cell therapies is Century Therapeutics (IPSC) developing?
